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Cyclic-RGD Peptides Increase the Adenoviral
Transduction of Human Mesenchymal Stem Cells
William J. King1 and Paul H. Krebsbach1,2
Human mesenchymal stem cells (hMSCs) have been extensively explored for drug delivery applications due to
their safety, immunomodulatory properties, and ability to differentiate into new tissues. The experiments
presented in this study were designed to determine peptide-based mechanisms to increase the adenoviral
transduction of hMSCs for the purpose of improving their capacity as drug delivery vehicles. Specifically, we
demonstrated that cyclic- RGD peptides increased the internalization of adenoviruses into MSCs. MSCs treated
with cyclic-RGD peptides had a transduction efficiency of 76.6% – 4%, which was significantly greater than the
23.5% – 12.2% transduction efficiency of untreated stem cells (P < 0.05). Blocking endocytosis with inhibitors of
dynamin or actin polymerization decreased the cyclic-RGD-mediated increase in transduction efficiency. MSCs
treated with cyclic-RGD and adenoviruses carrying the gene for bone morphogenetic protein-2 produced
significantly greater concentrations of this growth factor compared to stem cells treated with only adenoviruses
or adenoviruses cocultured with cyclic-RAD peptides. Furthermore, this stem cell-produced bone morphoge-
netic protein induced alkaline phosphatase expression in C2C12 cells indicating growth factor bioactivity. Taken
together, these studies suggest that cyclic-RGD peptides could be used to increase the adenoviral transduction of
hMSCs and increase their therapeutic potential.
Introduction
Several studies have demonstrated the capacity ofhuman mesenchymal stem cells (hMSCs) to differentiate
into functional adult cell types as well as their ability to
produce therapeutic extracellular factors. The National
Institutes of Health currently lists 129 clinical trials using
autologous and allogeneic hMSCs for diverse indications
(http://clinicaltrials.gov). To date, results from these trials
have indicated that hMSCs generally produce temporary
improvements that may be primarily attributed to their
production of soluble signaling molecules [1]. hMSCs have
several advantageous properties for drug delivery applica-
tions, including their ability to be expanded in culturewithout
losing their phenotype, their immunoprivileged nature, in-
nate immunomodulatory properties, their ability to produce
diverse extracellular factors, and their potential to home to
damaged tissue sites [2]. Therefore, hMSCs have been studied
as drug delivery vehicles for growth factors [3–5], proteases
[6], oncolytic adenoviruses [7], transcription factors [8], and
chemokine receptors [9]. In each of these applications,
increasing the capacity of hMSCs to produce extracellular
factors is critical for their therapeutic success.
An emerging approach to enhance the therapeutic effec-
tiveness of transplanted hMSCs has been to transduce them
with therapeutic adenoviruses. hMSCs have been transduced
with viruses containing the genes for diverse proteins, in-
cluding the coagulation factor IX [6], the bone morpho-
genetic protein-2 (BMP2) [10], the vascular endothelial
growth factor [11], interferon-b [12], and leptin [13]. For
example, hMSCs transduced with adenoviruses carrying the
gene for insulin-like growth factor-1 homed to ex-vivo
cultured bovine intervertebral disks and induced greater
proteoglycan synthesis compared to unmodified hMSCs [14].
Taken together, these results suggest that new methods to
increase the internalization of therapeutic viruses into
hMSCs could be broadly applied to increase their clinical
efficacy.
One potential mechanism to increase the adenoviral
transduction of hMSCs would be to harness their endoge-
nous internalization mechanisms using integrin-binding
peptides. Adenoviruses have been characterized during cell
entry to first bind to their primary coxsackie and adenovirus
receptors [15]. After docking with their primary receptors,
adenoviruses bind to integrins via their surface-exposed
RGD peptide sequence. This integrin binding initiates intra-
cellular processes, including endocytosis [16]. Critically, in-
tegrin binding has not been necessary for adenoviral
internalization [17]. In fact, linear GRGDSP peptides have
inhibited the adenoviral transduction of HeLa and M21 cells.
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Therefore, we sought to determine the effect of RGD peptide
sequence and structure on the transduction efficiency of
hMSCs.
In this study, we characterized the ability of RGD-based
peptides to increase the adenoviral transduction efficiency of
hMSCs and determined the extent to which the increased
transduction efficiency would translate to enhanced pro-
duction of therapeutic proteins. hMSCs from bone marrow
were chosen because they possess increased genetic stability
compared to hMSCs from other tissues [18]. RGD-based
peptides were chosen because of their well-characterized role
in integrin signaling, cell adhesion, biomaterials design,
and approval for use as an orphan drug by the European
Medicines Agency and the United States Food and Drug
Administration [19]. Therapeutic adenoviruses were charac-
terized in detail because they have been used to insert genes
into hMSCs [20,21] with greater efficiency than nonviral
transfection techniques [22]. Results demonstrated that
cyclic-RGD molecules enhanced the uptake of therapeutic
viruses. Cyclic-RGD peptides may have increased the inter-
nalization of adenoviruses through the endocytosis pathway.
The specific peptides increased the concentration of an
important therapeutic protein, BMP2, after transduction with
adenoviruses carrying the gene for BMP2. Significantly,
hMSC-produced BMP2 was bioactive and induced increased
alkaline phosphatase gene expression in C2C12 cells, which
have been the canonical test for BMP2 bioactivity [23]. These
studies suggest that cyclic-RGD peptides could be broadly
employed to increase the drug delivery potential of hMSCs
for diverse therapeutic indications.
Materials and Methods
Stem cell culture
hMSCs were purchased from Lonza (Walkersville, MD)
and grown in the a-MEM medium (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Gibco), and 1%
penicillin/streptomycin (Gibco). The cells were grown
following protocols to maintain their multipotency [24].
Twenty-four hours before transduction, hMSCs were pas-
saged into 24-well plates (Corning, Corning, NY) at a seed-
ing density of 1.3 · 104 hMSCs/cm2. Cyclic-RGD (RGDfV)
(capital letters =L amino acids, lower case letters =D amino
acids), Cyclic-RAD (RADfV) (Peptides International, Louis-
ville, KY), and linear-RGD peptides (GRGDSP) (Anaspec,
Fremont, CA) were diluted in phosphate-buffered saline
(PBS) (Gibco) and stored at - 20C until treatment. hMSCs
were imaged using an Eclipse TE2000-s (Nikon, Melville,
NY) inverted microscope controlled using NIS Elements D
3.1 software (Nikon).
Macromolecule internalization techniques
hMSCs were passaged into 24-well plates as previously
described to examine the effects of peptides on adenovirus
uptake. To quantify adenovirus internalization, hMSCs were
treated with predetermined cyclic-RGD concentrations and
adenoviruses carrying the gene for BMP2 (Ad-BMP2) (Uni-
versity of Michigan Vector Core, Ann Arbor, MI) at a mul-
tiplicity of infection (MOI) of 250 for 24 h. After the
incubation period, hMSCs were washed 4 times with 4C
PBS and fixed using Z-Fix (Anatech, Battle Creek, MI). The
cells were then treated with a mouse anti-adenovirus pri-
mary antibody and a fluorescein isothiocyanate-labeled goat
anti-mouse secondary antibody (Abcam, Cambridge, MA).
Bright field and fluorescent micrographs were collected and
greater than 10 micrographs per treatment were quantified
by normalizing the number of fluorescent cells to the total
number of cells per micrograph.
Transduction methods
Adenoviruses carrying the genes for the green fluorescent
protein (Ad-GFP) and Ad-BMP2 were acquired from the
University of Michigan Vector Core and diluted to their final
MOI using PBS (Gibco) containing 0.5% gelatin (Fisher
Scientific, Fairlawn, NJ). hMSCs were washed with PBS, and
then the diluted adenovirus was added in 0.25mL serum
containing the medium for 24 h. Then, the adenovirus con-
taining media was replaced with fresh hMSC media. The
transduction efficiency was measured using 2 techniques.
First, bright field and fluorescent micrographs of Ad-GFP-
transduced hMSCs were collected from 4 wells in a 24-well
plate and at least 10 micrographs were quantified per treat-
ment. To qualify this image-based analysis, hMSCs were
treated using the same procedure, and then their normalized
transduction efficiency was analyzed using a C6 Flow
Cytometer (BD Accuri Cytometers, Ann Arbor, MI).
Characterization of internalization pathways
The effect of cyclic-RGD peptides on endocytosis was
studied using pharmacological inhibitors that blocked
endocytosis. hMSCs in 24-well plates were treated for 30min
with 80mM Dynasore (Santa Cruz Biotechnology, Santa
Cruz, CA) or 5mM cytochalasin B (Fisher Scientific). The cells
were then washed with PBS and fresh hMSC media was
added with predetermined concentrations of cyclic-RGD and
Ad-GFP for 24 h. The hMSC transduction efficiency was then
measured using the previously described image-based
quantification techniques. To determine if these concentra-
tions were effective at blocking endocytosis, hMSCs were
treated with 1mg/mL Lucifer Yellow for 24 h (Fisher
Scientific). hMSCs were then washed 4 times with 4C PBS,
fixed using Z-Fix, and imaged using previously described
techniques.
Characterization of therapeutic relevance
To demonstrate the therapeutic relevance of this peptide-
based approach, hMSCs were tested as a drug delivery ve-
hicle for BMP2. First, hMSCs were treated with Ad-BMP2,
Ad-BMP2 + cyclic-RGD, Ad-BMP-2 + cyclic-RAD, Ad-GFP,
cyclic-RGD or they were maintained in the hMSC growth
medium for 24 h. The medium was collected and replaced
after 4 and 7 days. All experiments were performed in
0.25mL hMSC medium in 24-well plates (n= 6). The BMP2
concentration in the medium produced by hMSCs was
quantified using an enzyme-linked immunosorbent assay
(ELISA) kit following the manufacturer’s protocol (R&D
Systems, Minneapolis, MN).
C2C12 cells (ATCC, Manassas, VA), which upregulate
alkaline phosphatase expression in response to BMP2, were
used to evaluate the bioactivity of the hMSC-produced
BMP2. C2C12 cells were grown in the DMEM (Gibco) with
680 KING AND KREBSBACH
10% fetal bovine serum (Gibco), and 1% penicillin/strepto-
mycin (Gibco). C2C12 cells were passaged into 24-well plates
at a seeding density of 1.3 · 104 cells/cm2 and grown for 24 h.
The cells were then washed with PBS and grown in a con-
ditioned medium from the hMSCs treated with Ad-BMP2,
Ad-BMP2 + cyclic-RGD, Ad-BMP-2 + cyclic-RAD, Ad-GFP,
cyclic-RGD, or media from hMSCs that were left untreated.
The C2C12 cells were maintained in this conditioned me-
dium for 3 days, and then stained for alkaline phosphatase
activity using a Leukocyte Alkaline Phosphatase Kit fol-
lowing the manufacturer’s instructions (Sigma, St. Louis,
MO). All experimental conditions were performed in qua-
druplicate and repeated at least 5 times. The effect of cyclic-
RGD peptides alone on alkaline phosphatase activity in
C2C12 cells was tested by culturing them in increasing
concentrations of the peptide for 24 h. The medium was then
replaced with a fresh C2C12 medium; the cells were cultured
for an additional 3 days and finally stained for alkaline
phosphatase activity. Greater than 15 bright field micro-
graphs were collected per treatment and the number of
alkaline phosphatase expressing cells and the total num-
ber of cells were quantified using previously described
methods [25].
Results
Cyclic-RGD increased the transduction efficiency in a se-
quence, conformation, and concentration-dependent manner
(Fig. 1). For example, 1 day post transduction hMSCs treated
with cyclic-RAD peptides had a transduction efficiency of
6.3% – 1.0%, hMSCs treated with linear- RGD peptides had a
transduction efficiency of 15.4%– 10%, and hMSCs treated
with cyclic-RGD peptides had a transduction efficiency of
76.6% – 4% (Fig. 1A). Increasing the cyclic-RGD concentra-
tion increased the fraction of hMSCs expressing GFP
(Fig. 1B). At 2 days post-transduction, hMSCs maintained in
the growth medium had a transduction efficiency of
14.2% – 4.7%, whereas hMSCs exposed to 86 mM cyclic-RGD
peptides had a transduction efficiency of 78.4% – 18.8%.
Similar trends were observed when the transduction effi-
ciency was measured using both imaging and flow cytom-
etry-based techniques (Fig. 1C). The transduction efficiency
of hMSCs treated with high concentrations of cyclic-RGD
remained high over the course of the 7-day experiment.
Alternatively, the transfection efficiency of untreated hMSCs
increased over time, but did not achieve as high a trans-
duction efficiency as hMSCs treated with cyclic-RGD
FIG. 1. Cyclic-RGD peptides in-
fluence on the adenoviral trans-
duction of human mesenchymal
stem cells (hMSCs). (A) Effect of
amino acid sequence and confor-
mation on the adenoviral trans-
duction efficiency of hMSCs.
* Denotes significant increase from
86 mM cyclic-RAD (t-test, P< 0.05).
Error bars indicate standard devia-
tion. (B) Effect of cyclic-RGD pep-
tide concentration on the adenoviral
transduction efficiency of hMSCs.
* Denotes significant increase from
0mM cyclic-RGD (t-test, P< 0.05).
Error bars indicate standard devia-
tion. (C) Normalized transduction
efficiency of hMSCs treated with
predetermined concentrations of
cyclic-RGD peptides measured us-
ing a flow cytometer. * Denotes
significant increase from 0mM
cyclic-RGD (t-test, P< 0.05). Error
bars indicate standard deviation.
(D) Effects of cyclic RGD peptides
on the uptake of adenoviruses into
hMSCs. * Denotes significant in-
crease from 0mM cyclic-RGD (t-test,
P< 0.05). Error bars indicate stan-
dard deviation.
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peptides. For example, after 7 days, untreated hMSCs had a
transduction efficiency of 49.2% – 14.7%, whereas hMSCs
treated with 86 mM cyclic-RGD peptides had a transduction
efficiency of 94.8% – 6.3% (Fig. 1B). Also, the fraction of
hMSCs that internalized adenoviruses increased from
55.7% – 3.7% when they were maintained in the growth
medium to 87.6%– 8.5% when they were exposed to 86mM
cyclic-RGD (Fig. 1D).
After determining that the cyclic structure and the RGD
peptide sequence were both necessary to increase hMSC
transduction efficiency, we sought to determine if endocy-
tosis contributed to the ability of cyclic-RGD peptides to
enhance transduction. The role of endocytosis was studied
by blocking the endocytotic uptake of reporter molecules
with pharmacologic inhibitors. The pharmacological inhibi-
tor concentrations used in this study significantly decreased
the internalization of the small molecule fluorophore, Lucifer
Yellow (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/scd), which sug-
gested that these molecules and concentrations would be
appropriate for the characterization of the effects of cyclic-
RGD on endocytosis. One-day post-transduction 43mM
cyclic-RGD increased the transduction efficiency to
57.1% – 6.6%. In contrast, when hMSCs were exposed to
Dynasore and 43mM cyclic-RGD, they had an adenoviral
transduction efficiency of 2.1% – 2.5% (Fig. 2A). Unlike
previously observed trends (Fig. 1B), increasing the concen-
tration of cyclic- RGD did not induce greater hMSC trans-
duction efficiencies when endocytosis was blocked with
Dynasore. Even 7-days post-treatment, hMSCs treated with
Dynasore and 43 mM cyclic-RGD had a transduction effi-
ciency of 0.8%– 1% (Fig. 2A). The endocytosis inhibitor
cytochalasin B also significantly decreased the ability of
cyclic-RGD to enhance the transduction of hMSCs (P < 0.05).
Seven days post-transduction, hMSCs treated with cyto-
chalasin B and 43mM cyclic-RGD or 86mM cyclic-RGD had
transduction efficiencies of 2.8%–2.7% and 2.9%–4.0%,
respectively. Alternatively, hMSCs treated with 43mM cyclic-
RGD alone had a transduction efficiency of 34%–17% (Fig. 2B).
After demonstrating that endocytosis contributed to the
ability of cyclic-RGD peptides to enhance the Ad-GFP
transduction of hMSCs, it was critical to test if these results
would extend to therapeutically relevant proteins. Sig-
nificantly, cyclic-RGD peptides enhanced the adenoviral-
induced production of BMP2 (Fig. 3). hMSCs maintained in
the growth medium treated with Ad-GFP or treated with
cyclic-RGD peptides produced lower BMP2 concentrations
compared to hMSCs transduced with Ad-BMP2 (Fig. 3A). In
contrast, when hMSCs were treated with cyclic- RGD pep-
tides and Ad-BMP2, they produced 413 – 192 ng/mL BMP2
in a medium collected from day 5–7, which was a signifi-
cantly greater (P < 0.05) BMP2 concentration than when they
were treated with Ad-BMP2 alone.
The hMSC-produced BMP2 induced osteogenic gene ex-
pression in C2C12 cells (Fig. 3B, C). The conditioned medium
from Ad-BMP2-transduced hMSCs significantly increased
the fraction of C2C12 cells expressing alkaline phosphatase
compared to C2C12 cells grown in the conditioned medium
from untreated hMSCs (P < 0.05). C2C12 cells exposed to a
medium that was conditioned by hMSCs treated with
Ad-BMP2 and cyclic-RGD had a significantly greater alkaline
phosphatase activity than the medium from both untreated
hMSCs and hMSCs transduced with Ad-BMP2 alone
(P< 0.05). In contrast, C2C12 cells treated with the condi-
tioned medium from hMSCs exposed to Ad-BMP2 with cy-
clic-RAD had an increased alkaline phosphatase activity
compared to the medium from untreated hMSCs, but did not
have a significantly greater alkaline phosphatase activity
FIG. 2. Cyclic-RGD mediated increase in the adenoviral transduction efficiency of hMSCs using small molecule inhibitors of
endocytosis. (A) Effect of endocytosis inhibitor, Dynasore, and cyclic-RGD peptides on the adenoviral transduction efficiency
of hMSCs. * Denotes significant difference from treatment with adenovirus alone (t-test, P < 0.05). Error bars indicate standard
deviation. (B) Effect of cytochalasin B, another endocytosis inhibitor and cyclic-RGD peptides on the adenoviral transduction
efficiency of hMSCs. * Denotes significant difference from treatment with adenovirus alone (t-test, P < 0.05). Error bars
indicate standard deviation.
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compared to conditioned media from hMSCs treated with
Ad-BMP2 alone (P < 0.05). The medium collected from
hMSCs transduced with Ad-GFP did not significantly in-
crease the percentage of C2C12 cells expressing alkaline
phosphatase. C2C12 cells exposed to the conditioned me-
dium from hMSCs treated with cyclic-RGD had significantly
increased alkaline phosphatase activity compared hMSCs
maintained in growth media from days 1–4 (P < 0.05), but did
not increase alkaline phosphatase activity from days 4–7.
C2C12 cells exposed to the conditioned medium from
hMSCs treated with cyclic-RGD induced significantly less
alkaline phosphatase activity compared to media from
hMSCs treated with Ad-BMP2 (P< 0.05) (Fig. 3B, C, i–vi).
When C2C12 cells were grown in the C2C12 medium with
increasing concentrations of cyclic-RGD peptides, no in-
crease in the expression of alkaline phosphatase was ob-
served (Supplementary Fig. S2, i–vi).
Discussion
Approaches to enhance the adenoviral transduction of
hMSCs could be broadly used to enhance their drug delivery
capabilities and therapeutic potential. hMSCs have internal-
ized adenoviruses carrying genes to induce their production
of therapeutic proteins [6]. However, hMSCs have been dif-
ficult to transduce with adenoviruses and required MOI’s
greater than 1,000 [21,26] and up to 3,000 [12]. Therefore, in
this study we explored the effects of RGD-peptides on the
internalization and transduction efficiency of therapeutic
viruses. We characterized the effects of peptide sequence,
conformation, and concentration on the adenoviral trans-
duction efficiency of hMSCs and the production of biological
drugs. Our results suggest that each of these parameters
affects the adenoviral transduction efficiency of hMSCs and
cyclic-RGD peptides may be broadly useful in increasing
their therapeutic capabilities.
Cyclic-RGD peptides increased the internalization of
model therapeutic viruses into hMSCs. Cyclic-RGD peptides
have been covalently immobilized or genetically engineered
into polymers [27], proteins [28], and therapeutic viruses to
increase their internalization into cells [29]. However, these
approaches could denature the biomolecules and have
required reaction and purification schemes. Therefore, we
sought to further characterize the effects of solution-phase
FIG. 3. Effect of cyclic-RGD
peptides on the Ad-BMP2-in-
duced expression of BMP2. (A)
BMP2 concentration produced
by hMSCs maintained in
growth medium, treated with
Ad-BMP2, Ad-BMP2+ cyclic-
RGD,Ad-BMP2+ cyclic-RAD,
Ad-GFP, or cyclic-RGD. (B)
Percent of alkaline phospha-
tase expressing C2C12 cells
treated with conditioned me-
dia from hMSCs exposed to
growthmedia, Ad-BMP2, Ad-
BMP2 + cyclic-RGD, Ad-
BMP2 + cyclic-RAD, Ad-GFP,
or cyclic-RGD. * Denotes sig-
nificant difference from
hMSCs maintained in growth
media. Error bars indicate
standard deviation. (C) Re-
presentative micrographs of
C2C12 cells exposed to con-
ditioned media from hMSCs
treated with growth media,
Ad-BMP2, Ad-BMP2+ cyclic-
RGD, Ad-BMP2 + cyclic
RAD, Ad-GFP, or cyclic-RGD.
BMP2, bone morphogenetic
protein-2. {, Denotes sig-
nificant difference from
hMSCs transduced with Ad-
BMP2 (t-test, P < 0.05).
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cyclic-RGD peptides on enhancing the transduction of
hMSCs with therapeutic adenoviruses.
Peptides that had the RGD sequence in a cyclical structure
increased the adenoviral transduction efficiency of hMSCs in
a concentration-dependent manner. Previous studies have
demonstrated that linear-RGD peptides inhibited the ade-
noviral transduction of hMSCs. However, these concentra-
tions were 349% and 1977% greater than the highest
concentrations of linear-RGD used in the experiments per-
formed in this study [17]. Cyclic-RGD may have been more
effective than linear-RGD in enhancing the transduction of
hMSCs due to its enhanced stability or its increased affinity
for avb3 integrins (Fig. 1A). Cyclic-RGD peptides have been
measured to be 30 times more stable than linear-RGD pep-
tides at pH 7 [30]. Furthermore, the cyclic-RGD peptide used
in this study had a lower IC50 of 0.1–1.0mM when compared
to the linear-RGD peptide, which had an IC50 of 4–100mM for
the inhibition of cell adhesion to recombinant laminin frag-
ments [31]. It will be critical to understand the stability and
binding kinetics of these peptides in future studies, as both
peptides and adenoviruses undergo rapid degradation in cell
culture environments.
Cyclic-RGD peptides may have increased the internali-
zation of adenoviruses through the dynamin-mediated
endocytosis pathway (Fig. 2). Blocking dynamin inhibits
phagocytosis, caveolar endocytosis, and clathrin-dependent
endocytosis [32]. Understanding which internalization
pathway is used by different biomacromolecules could have
significant consequences, as different internalization path-
ways have resulted in different functional outcomes. For
example, Dhaliwal and colleagues demonstrated that mouse
MSCs cultured on fibronectin internalized plasmid DNA-
polyethyleneimine particles primarily through endocytosis
and these MSCs had significantly greater transgene expres-
sion than mouse MSC grown on collagen-I, which inter-
nalized particles primarily through macropinocytosis and
caveolae-mediated endocytosis [33]. Understanding not only
the internalization pathway, but also how the hMSCs’ en-
vironment affects internalization will be important for drug
delivery applications. Recent studies have characterized the
effect of the microenvironment on the internalization of
biomacromolecules into stem cells. For example, the effect of
nanotopography [34] and encapsulation in biomaterials [35]
has been explored on the internalization of adenoviruses. For
example, hMSCs transduced with Ad-BMP2 in three-
dimensional (3D) alginate hydrogels produced 7.41-fold
more BMP2 than when they were transduced first in 2D
culture, and then encapsulated in 3D hydrogels [35]. These
approaches could be applied with the solution-phase cyclic-
RGD-mediated approach delineated in this manuscript to
further enhance the transduction efficiency of hMSCs.
Cyclic-RGD peptides increased the concentration of BMP2
produced by hMSCs after transduction with Ad-BMP2.
Significantly, the concentration of BMP2 secreted by hMSCs
in this study, 0.41 – 0.19 mg/mL, was similar to or greater
than the BMP2 concentration included in gelatin hydrogel
disks to induce bone formation in preclinical animal studies
(Fig. 3A) [36], which suggests that this technique could be
extended to animal testing in future studies. Also, it is sig-
nificant to note that the BMP2 produced by hMSCs in this
study was able to induce alkaline phosphatase expression in
C2C12 cells, which have been the canonical assay for BMP2
bioactivity (Fig. 3B, C) [23]. Protein overexpression could
lead to misfolding and the production of proteins that do not
illicit the desired therapeutic response [37]. A potential ad-
vantage of this approach is that cyclic-RGD and therapeutic
adenoviruses could be included in the work flow of bedside
stem cell purifying machines that are currently undergoing
clinical trials, which could remove the time and expense of
ex-vivo manipulation [38]. Therefore, this approach could be
broadly applicable due to the ability of adenoviruses to carry
genes for a wide variety of therapeutic proteins.
The conditioned medium from hMSCs treated with cyclic-
RGD peptides alone increased alkaline phosphatase expres-
sion in C2C12 cells (Fig. 3C, i–vi), whereas C2C12 cells
treated directly with cyclic-RGD peptides did not have an
increased alkaline phosphatase activity (Supplementary Fig.
S2). This finding suggested that the peptides may have in-
duced hMSCs to secrete one or more pro-osteogenic factors.
Several studies have demonstrated that cyclic-RGD peptides
alone can induce a pro-osteogenic response, but when pre-
sented differently than in the culture medium used in this
study. In one study, hMSCs cultured in alginate hydrogels
with covalently immobilized linear RGD peptides were un-
able to induce osteocalcin expression, whereas covalently
immobilized cyclic-RGD peptides induced osteocalcin ex-
pression and secretion [39]. In an in vivo sheep model, cyclic-
RGD was as effective at inducing spine fusion as BMP2 when
each drug was delivered from a mineralized collagen matrix
[40]. Multiple secreted molecules have been implicated in
directing stem cell osteogenic differentiation, including BMP
family members [41], glucocorticoids [42], parathyroid hor-
mone [43], and oxysterols [44]. Furthermore, recent studies
have identified hundreds of proteins in hMSCs’ secretome
during medium-induced osteogenic differentiation [45,46].
Therefore, in future studies, it will be interesting to harness
these techniques to measure the change in proteins secreted
by hMSCs when they interact with cyclic-RGD peptides
presented in different contexts.
Conclusions
In this manuscript, we characterized the use of cyclic-RGD
peptides to enhance the transduction efficiency of adeno-
viruses. The enhanced uptake of therapeutic viruses was spe-
cific for peptides with the cyclic structure and RGD amino acid
sequence. The increased transduction efficiency was depen-
dent upon the peptide concentration in the culture medium.
Blocking endocytosis with pharmacological agents inhibited
the cyclic-RGD-mediated increase in adenoviral transduction
efficiency. As a proof of therapeutic principle, cyclic-RGD
peptides increased the adenoviral-induced production of an
important therapeutic protein, BMP2. The enhanced BMP2
concentrations produced by hMSCs increased the alkaline
phosphatase expression in C2C12 cells, which have been
extensively used to measure BMP2 bioactivity. Taken to-
gether, this approach to enhancing the adenoviral transduc-
tion efficiency of hMSCs here could be used to increase the
drug-delivering capability of hMSCs in future studies.
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